A precision medicine approach to therapeutic resistance using KEAP1 somatic mutations

Gene expression in primary non-small cell lung cancer as a predictor of brain metastases

Rewriting the code of life: CRISPR-Cas9 genome editing

Lifestyle-based prevention strategies to decrease cancer risk

Rapidly changing landscape of precision medicine in Japan

Use of platform studies for the evaluation of innovative combinations in solid tumours and haematologic malignancies

Direct targeting of STAT3 alone and in combination with immune checkpoint inhibitors to treat solid tumours

Integration of DNA and RNA investigations in clinical trials: A laboratory challenge

Optimising patient enrolment and efficacy of precision oncology clinical trials

Innovative algorithms and IT platform to support clinical trials

Implementing national cancer control plans

Comment: POLO III trial for metastatic pancreatic cancer